Kenya - English - Pharmacy and Poisons Board

dolutegravir sodium - film-coated tablet - dolutegravir sodium tablet for oral suspension… - dolutegravir

Kenya - English - Pharmacy and Poisons Board

cipla quality chemical industries limited plot 1 - 7, 1st ring road, luzira industrial - dolutegravir sodium, lamivudine and tenofovir… - tablet - dolutegravir sodium 50mg, lamivudine 300mg and… - direct acting antivirals

United States - English - NLM (National Library of Medicine)

viiv healthcare company - dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), rilpivirine hydrochloride (unii: 212wax8kdd) (rilpivirine - unii:fi96a8x663) - dolutegravir 50 mg - juluca is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of juluca. juluca is contraindicated in patients:    •    with previous hypersensitivity reaction to dolutegravir or rilpivirine [see warnings and precautions (5.1)] .    •    receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see drug interactions (7)] .    •    receiving other coadministered drugs in table 1 that significantly decrease rilpivirine plasma concentrations [see drug interactions (7), clinical pharmacology (12.3)] . drug class contraindicated drugs in class clinical comment antia

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1) - dolutegravir 50 mg - tivicay is indicated in combination with: tivicay is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to tivicay during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary there are insufficient human data on the use of tivicay during pregnancy to inform a drug-associated risk of birth defects and miscarriage. given the limited number of pregnancies exposed to dolutegravir-based regimens reported to the apr, no definitive conclusions can be drawn on the safety of tivicay in pregnancy, and continued monitoring is ongoing through the apr. the background rate for major birth defects in a u.s. reference population of the metropolitan atlanta congenital defects program (macdp) is 2.7%. the rate of miscarriage is not reported in the apr. the estimated background rate of miscarriage in clinically recognized pregnancies

United States - English - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - triumeq and triumeq pd are indicated for the treatment of hiv-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. limitations of use: triumeq and triumeq pd alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (insti) resistance because the dose of dolutegravir in triumeq and triumeq pd is insufficient in these subpopulations. see full prescribing information for tivicay (dolutegravir). triumeq and triumeq pd are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to triumeq during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1‑800‑258‑4263. risk summary data from an ongoing birth outcome surveillance study has identified an increased risk of neural tube defects when dolutegravir, a componen

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir sodium, quantity: 10.5 mg (equivalent: dolutegravir, qty 10 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; sodium stearylfumarate; mannitol; microcrystalline cellulose; povidone; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir sodium, quantity: 26.3 mg (equivalent: dolutegravir, qty 25 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; sodium stearylfumarate; mannitol; microcrystalline cellulose; povidone; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; iron oxide yellow - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

sun pharmaceutical industries limited, india - dolutegravir sodium - tablet, film-coated - 50 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - dolutegravir sodium, lamivudine , tenofovovir disoproxil fumarate - oral tablet - dolutegravir 50mg, lamivudine 300mg and tenofovir disoproxil fumerate 300mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1) - dolutegravir 50 mg